Excipients for protein drugs

Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems

Volumn , Issue , 2006, Pages 291-331

  Gokarn, Yatin R ^a   Kosky, Andrew ^a   Kras, Eva ^a   McAuley, Arnold ^a   Remmele, Richard L ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84940652626     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (71)

1. Walsh G. Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol 2005; 23(11): 553-557.
2. Robbins DC, Hirshman M, Wardzala LJ, Horton ES. High-molecular-weight aggregates of therapeutic insulin. In vitro measurements of receptor binding and bioactivity. Diabetes 1988; 37(1): 56-59.
3. Patten PA, Schellekens H. The immunogenicity of biopharmaceuticals: lessons learned and consequences for protein drug development. In: Brown F, Mire-Sluis AR, eds. Immunogenicity of Therapeutic Biological Products. Basel, Switzerland: S. Karger, 2003.
4. Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004; 21: 897-903.
5. Schellekens H. Bioequivalence and immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1(6): 457-462.
6. Hermeling S, Aranha L, Damen JM, et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 2005; 22(12): 1997-2006.
7. Hasselbeck A. Epoetins: differences and their relevance to immunogenicity. Curr Med Res Opin 2003; 19(5): 430-432.
8. Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity?. Pharm Res 2003; 20(12): 1903-1907.
9. Schellekens H, Crommelin DJ. Equivocal role of micelles in Eprex adverse events. Nat Biotechnol 2003; 21(11): 1265.
10. PDR Electronic Library™ Online: © 2002-2006. Thomson PDR.
11. Spada S, Walsh G, ed. Directory of Approved Biopharmaceutical Products. Boca Raton, Florida: CRC Press LLC, 2005: 33431.
12. Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 2005; 94(2): 256-274.
13. Treuheit MJ, Kosky AA, Brems DN. Inverse relationship of protein concentration and aggregation. Pharm Res 2002; 19(4): 511-516.
14. Jones LS, Kaufmann A, Middaugh CR. Silicone oil induced aggregation of proteins. J Pharm Sci 2005; 94(4): 918-927.
15. Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 2003; 20(9): 1325-1336.
16. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 2005; 289(1-2): 1-30.
17. Gregersen N, Bolund L, Bross P. Protein misfolding, aggregation, and degradation in disease. Mol Biotechnol 2005; 31(2): 141-150.
18. Dobson CM. Protein folding and misfolding. Nature 2003; 426(6968): 884-890.
19. Lumry R, Eyring H. Conformation changes of proteins. J Phys Chem 1954; 58: 110-120.
20. Oliyai C, Borchardt RT. Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm Res 1993; 10(1): 95-102.
21. Oliyai C, Borchardt RT. Chemical pathways of peptide degradation. VI. Effect of the primary sequence on the pathways of degradation of aspartyl residues in model hexapeptides. Pharm Res 1994; 11(5): 751-758.
22. Patel K, Borchardt RT. Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide. Pharm Res 1990; 7(7): 703-711.
23. Bhatt NP, Patel K, Borchardt RT. Chemical pathways of peptide degradation. I. Deamidation of adrenocorticotropic hormone. Pharm Res 1990; 7(6): 593-599.
24. Patel K, Borchardt RT. Chemical pathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides. Pharm Res 1990; 7(8): 787-793.
25. Brennan TV, Clarke S. Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: effects of the solvent dielectric. Protein Sci 1993; 2(3): 331-338.
26. Costantino HR, Langer R, Klibanov AM. Moisture induced aggregation of lyophilized insulin. Pharm Res 1994; 11: 21-29.
27. Schoneich C, Zhao F, Wilson GS, Borchardt RT. Iron-thiolate induced oxidation of methionine to methionine sulfoxide in small model peptides. Intramolecular catalysis by histidine. Biochim Biophys Acta 1993; 1158(3): 307-322.
28. Goolcharran C, Khossravi M, Borchardt RT. Chemical pathways of peptide and protein Degradation. In: Frokjaer S, Hovgaard L, eds. Pharmaceutical Formulation Development of Peptides and Proteins. (Pharmaceutical Science.) U.K.: Taylor and Francis, 1999.
29. CPMP/CVMP/QWP/115/95 Note for Guidance on Inclusion of Antioxidants and Antimicrobial Preservatives in Medicinal Products, 1997.
30. CPMP/QWP/155/96 Note for guidance on development pharmaceutics (CPMP adopted Jan. 98).
31. Chang BS, Hershenson S. Practical approaches to protein formulation development. Pharm Biotechnol 2002; 13: 1-25.
32. Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci 2004; 93(6): 1390-1402.
33. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 1999; 185(2): 129-188.
34. Carpenter JF, Chang BS, Garzon-Rodriguez W, Randolph TW. Rational design of stable lyophilized protein formulations: theory and practice. Pharm Biotechnol 2002; 13: 109-133.
35. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000; 203(1-2): 1-60.
36. Ediger MD, Angell CA, Nagel SR. Supercooled liquids and glasses. J Phys Chem 100(31): 13200-13212.
37. Arakawa T, Kita Y, Carpenter JF. Protein-solvent interactions in pharmaceutical formulations. Pharm Res 1991; 8(3): 285-291.
38. Kendrick BS, Li T, Chang BS. Physical stabilization of proteins in aqueous solution. In: Carpenter JF, Manning MC, eds. Rational Design of Stable Protein Formulations: Theory and Practice. Pharmaceut Biotechnol 2002; 13: 61-84.
39. Randolph TW, Jones LS. Surfactant-protein interactions. Pharm Biotechnol 2002; 13: 159-175.
40. m plateau: a matter of thermal reversibility. Biochemistry 1999; 38(16): 5241-5247.
41. Laursen T, Hansen B, Fisker S. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol 2006; 98(2): 218-221.
42. Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. Am Fam Physician 2006; 73(2): 283-290.
43. Cacace MG, Landau EM, Ramsden JJ. The Hofmeister series: salt and solvent effects on interfacial phenomena. Quart Rev Biophys 1997; 30(3): 241-277.
44. Yamasaki M, Yano H, Aoki K. Differential scanning calorimetric studies on bovine serum albumin: II. Effects of neutral salts and urea. Int J Biol Macromol 1991; 13(6): 322-328.
45. Robinson NE, Robinson AB. Molecular Clocks. In: Deamidation of Asparaginyl and Glutaminyl Residues in Peptides and Proteins. Cave Junction, Oregon: Althouse Press, 2004.
46. Callahan WJ, Narhi LO, Kosky AA, Treuheit MJ. Sodium chloride enhances the storage and conformational stability of BDNF and PEG-BDNF. Pharm Res 2001; 18(3): 261-266.
47. Liu J, Nguyen MD, Andya JD, Shire SJ. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 2005; 94(9): 1928-19240 [Erratum in: J Pharm Sci 2006; 95(1): 234-235.].
48. Chen B, Bautista R, Yu K, Zapata GA, Mulkerrin MG, Chamow SM. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms. Pharm Res 2003; 20(12): 1952-1960.
49. Tomita M, Irie M, Ukita T. Sensitized photooxidation of histidine and its derivatives. Products and mechanism of the reaction. Biochemistry 1969; 8(12): 5149-5160.
50. Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 1997; 86(11): 1250-1255.
51. Arakawa T, Timasheff SN. Preferential interactions of proteins with solvent components in aqueous amino acid solutions. Arch Biochem Biophys 1983; 24(1): 169-177.
52. Tsumoto K, Umetsu M, Kumagai I, Ejima D, Philo JS, Arakawa T. Role of arginine in protein refolding, solubilization, and purification. Biotechnol Prog 2004; 20(5): 1301-1308.
53. Lin TY, Timasheff SN. On the role of surface tension in the stabilization of globular proteins. Protein Sci 1996; 5(2): 372-381.
54. Chevalier F, Chobert JM, Dalgalarrondo M, Choiset Y, Haertle T. Maillard glycation of beta-lactoglobulin induces conformation changes. Nahrung 2002; 46(2): 58-63.
55. Humeny A, Kislinger T, Becker CM, Pischetsrieder M. Qualitative determination of specific protein glycation products by matrix-assisted laser desorption/ionization mass spectrometry Peptide mapping. J Agric Food Chem 2002; 50(7): 2153-2160.
56. Kautz CF, Robinson AL. The hydrolysis of sucrose by hydrochloric acid in the presence of alkali and alkaline earth chlorides. JACS 1928; 50(4): 1022-1030.
57. Lee LL, Lee JC. Thermal stability of proteins in the presence of poly(ethylene glycols). Biochemistry 1987; 26(24): 7813-7819.
58. Bam NB, Cleland JL, Yang J, et al. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci 1998; 87(12): 1554-1559.
59. Akers MJ, Defelippis MR. Peptides and proteins as parenteral solutions. In: Frokjaer S, Hovgaard L, eds. Pharmaceutical Formulation Development of Peptides and Proteins. (Pharmaceutical Science.) U.K.: Taylor and Francis, 1999.
60. Tsai PK, Volkin DB, Dabora JM, et al. Formulation design of acidic fibroblast growth factor. Pharm Res 1993; 10(5): 649-659.
61. Fransson JR. Oxidation of human insulin-like growth factor I in formulation studies. 3. Factorial experiments of the effects of ferric ions, EDTA, and visible light on methionine oxidation and covalent aggregation in aqueous solution. J Pharm Sci 1997; 86(9): 4046-4050.
62. Yin J, Chu JW, Ricci MS, Brems DN, Wang DI, Trout BL. Effects of antioxidants on the hydrogen peroxide-mediated oxidation of methionine residues in granulocyte colony-stimulating factor and human parathyroid hormone fragment 13-34. Pharm Res 2004; 21(12): 2377-2383.
63. Kaisheva EA, Gupta S, Flores-Nate A. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization. PCT Int Appl WO 2004039337 A2 20040513 (2004).
64. Chen B, Costantino HR, Liu J, Hsu CC, Shire SJ. Influence of calcium ions on the structure and stability of recombinant human deoxyribonuclease I in the aqueous and lyophilized states. J Pharm Sci 1999; 88(4): 477-482.
65. Fatouros A, Osterberg T, Mikaelsson M. Recombinant factor VIII SQ-influence of oxygen, metal ions, pH and ionic strength on its stability in aqueous solution. Int J Pharm 1997; 155: 121-131.
66. Derrick TS, Kashi RS, Durrani M, Jhingan A, Middaugh CR. Effect of metal cations on the conformation and inactivation of recombinant human factor VIII. J Pharm Sci 2004; 93(10): 2549-2557.
67. Roy S, Jung R, Kerwin BA, Randolph TW, Carpenter JF. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. J Pharm Sci 2005; 94(2): 382-396.
68. Remmele RL Jr, Nightlinger NS, Srinivasan S, Gombotz WR. Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry. Pharm Res 1998; 15(2): 200-208.
69. Kappelgaard AM, Bojesen A, Skydsgaard K, Sjogren I, Laursen T. Liquid growth hormone: preservatives and buffers. Horm Res 2004; 62(suppl 3): 98-103.
70. Minogue SC, Sun DA. Bacteriostatic saline containing benzyl alcohol decreases the pain associated with the injection of propofol. Anesth Analg 2005; 100(3): 683-686.
71. Bam NB, Cleland JL, Randolph TW. Molten globule intermediate of recombinant human growth hormone: stabilization with surfactants. Biotechnol Prog 1996; 12(6): 801-809.